Haoyue Xu's research while affiliated with Xuzhou Medical College and other places

Publications (10)

Article
Correction for ‘Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation’ by Zongren Zhao et al. , Biomater. Sci. , 2020, 8 , 5306–5316, DOI: 10.1039/D0BM00338G.
Article
Glioma is the most prevalent type of malignant brain tumor and is usually very aggressive. Because of the high invasiveness and aggressive proliferative growth of glioma, it is difficult to resect completely or cure with surgery. Residual glioma cells are a primary cause of postoperative recurrence. Herein, we describe a hypoxia-responsive lipid po...
Article
Correction for ‘Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation’ by Zongren Zhao et al. , Biomater. Sci. , 2020, DOI: 10.1039/d0bm00338g.
Article
Glioma is the most aggressive primary malignant brain tumor. It is failed to eradicate the gliomas by performing neurosurgery due to the diffuse nature of malignant gliomas. Temozolomide (TMZ) is the first-line agent in treating gliomas after surgery, and its therapeutic efficacy is limited mainly due to high activity levels of the DNA repair prote...
Article
Full-text available
Introduction: Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Therefore, to limit TMZ resistance in glioma, an angi...
Article
Full-text available
The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GBM). However, TMZ + RT causes excess toxicity in patients. In this study, we prepared angiopep-2 (A2) modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles for TMZ delivery (A2-P(MIs)25/TMZ) to achieve synergistic effects agai...
Article
Full-text available
Glioblastoma is one of the most aggressive types of brain tumor. Epidermal growth factor receptors (EGFRs) are overexpressed in glioma, and EGFR amplifications and mutations lead to rapid proliferation and invasion. EGFR-targeted therapy might be an effective treatment for glioma. Gefitinib (Ge) is an EGFR tyrosine kinase inhibitor (TKI), and Golgi...
Article
Radiotherapy (RT) has become one of the most effective treatments for malignant tumor. Intra-tumoral hypoxia is recognized as a chief reason that induces resistance to radiation. Moreover, the toxicities of RT to normal tissues limits the usage of high doses of radiation to eliminate cancer cells. Therefore, developing an effective radiosensitizer...

Citations

... Therefore, a hypoxia-responsive lipid polymer nanoparticle (LN) has been developed for fluorescence-oriented surgery, chemotherapy, PDT, and PTT combined with multitherapy strategies for targeting glioma. 73 At present, most PDA NP drugs are loaded by π-π stacking. Zhang et al showed that a pH sensitive polymeric pro-drug was modified on the surface of PDA NPs by amidation chemistry for alliance of chemotherapy with photothermal treatment. ...
... Recently, stimuli-responsive injectable hydrogels, which have the capability to sense variations in pH 13 , temperature 14 , redox potential 15 , light 16 , electrical signals 17 , or enzymes 18 and respond by changing their shape or undergoing sol-gel transition, have been developed. Specifically, redox-responsive hydrogels, which exploit disease-specific redox variation as a trigger to prompt a diagnostic signal or to deliver a therapeutic molecule, have attracted considerable attention. ...
... To this end, PLK1 is reported to increase the temozolomide sensitivity in glioma stem cells [91]. Recently, the combination of temozolomide and PLK1 inhibitor has shown synergistic cytotoxicity in glioma cells in vivo [92]. USP9X (ubiquitin-specific peptidase 9 X-linked) is a deubiquitinase which regulates the protein levels of its substrates through proteasomal degradation. ...
... Liposome-based co-delivery systems most widely employ cationic liposomes (CLs), polymeric liposomes, and polymeric micelles. These formulations have already been used to deliver vascular endothelial growth factor (VEGF) siRNA-metformin ( Fig. 3 A) (Shi et al., 2017), signal transducer and activator of transcription 3 (STAT3) siRNA-curcumin (Jose et al., 2018), ribosomal protein S7 (RPS7) siRNA-endostatin , STAT3 siRNA-curcumin , Golgi phosphoprotein 3 (GOLPH3) siRNA-gefitinib (Ye et al., 2020), and insulin-like growth factor 1 (IGF-1R) siRNA-7-O-geranyl-quercetin to tumor cells in non-small cell lung carcinoma, skin cancer, colon carcinoma, lung adenocarcinoma, non-small cell lung cancer (NSCLC), epidermoid cancer, glioma, and NSCLC, respectively. Jose et al. encapsulated STAT3 siRNA and curcumin in cationic liposomes, as nanocarriers, to simultaneously target them against skin cancer cells, resulting in synergism between them in inducing apoptosis in and inhibiting the growth of malignant cells Jose et al., 2018). ...
... Therapies targeting EGFR are promising methods for glioma treatment. Gefitinib (Ge) is an EGFR tyrosine kinase inhibitor (TKI), which cannot enter the brain parenchyma due to the BBB (Ye et al., 2019). Therefore, effective strategies for Ge transporting are needed. ...
... In this way, gold nanospheres [55], nanorods [56], and nanoprisms [57] have been directed to the brain in animal models. For example, Angiopep-2-modified hypoxic lipid radiosensitizer-coated gold NPs were shown to enhance the effects of radiation therapy on brain tumor growth in vivo [58]. ...
... The RMCT strategies have been extensively employed in glioma targeting research, whose mechanism is based on the interaction between the targeting ligands and the receptors expressed in the brain. The receptors involve in transferrin receptor (TFR) (Luo et al. 2019;Choudhury et al. 2018;Kang et al. 2020), low-density lipoprotein receptor-related protein receptor (LRPR) (Zong et al. 2019;Han et al. 2018), insulin receptor (IR) (Bonnin et al. 2017), nicotinic acetylcholine receptor (NAR) (Clarke et al. 2021;Pucci et al. 2021), etc. To achieve RMCT strategies, two methods have been adopted. ...